John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
MIGDAL HA'EMEQ, Israel, Feb. 03, 2016 -- Enzymotec Ltd. (NASDAQ:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients and medical foods, today announced that the Company will release financial results for the fourth quarter and full year ended December 31, 2015 on Wednesday, February 17, 2016, before the market opens. Following the release, Dr. Ariel Katz, President and Chief Executive Officer, and Oren Bryan, Vice President and Chief Financial Officer, will host a conference call to review the financial results.
The conference call is scheduled to begin at 8:30 a.m. ET on Wednesday, February 17, 2016. Participants should dial (877) 359-9508 (United States) or (224) 357-2393 (International) with confirmation code 42574817 to access the live call. The call will also be broadcast live over the Internet, hosted in the Investors section of Enzymotec's website at http://edge.media-server.com/m/p/nznghg4j, and will be archived online within one hour of its completion through February 24, 2016.
About Enzymotec Ltd.
Enzymotec Ltd. is a leading global supplier of specialty lipid-based products and solutions. The Company develops, manufactures and markets innovative bio-active lipid ingredients, as well as final products, based on sophisticated processes and technologies. For more information, visit www.enzymotec.com.
CONTACT: The Ruth Group Tram Bui / Lee Roth (646) 536-7035/7012 [email protected] [email protected]
